Get the Stockscreener App
37.79
0.05%
-0.02
Pre-market:
37.51
-0.28
-0.74%
ARK Genomic Revolution ETF stock is traded at $37.79, with a volume of 1.63M.
It is down -0.05% in the last 24 hours and down -8.79% over the past month.
The investment seeks long-term growth of capital.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
See More
Previous Close:
$37.81
Open:
$38.39
24h Volume:
1.63M
Relative Volume:
0.51
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.28%
1M Performance:
-8.79%
6M Performance:
+16.56%
1Y Performance:
+45.35%
1-Day Range:
$37.51
$38.96
1-Week Range:
$37.51
$39.70
52-Week Range:
$22.73
$44.47
ARK Genomic Revolution ETF Stock (ARKG) Company Profile
Name
ARK Genomic Revolution ETF
Sector
Industry
Phone
855-406-1506
Address
-
Compare ARKG vs VTI, SPY, IVV, VB, QQQ
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARKG
ARK Genomic Revolution ETF
|
37.79 | 0 | 0 | 0 | 0 | 0.00 |
VTI
Vanguard Total Stock Market Etf
|
365.18 | 417.53B | 0 | 0 | 0 | 0.00 |
SPY
Spdr S P 500 Etf Trust
|
739.09 | 372.57B | 0 | 0 | 0 | 0.00 |
IVV
Ishares Core S P 500 Etf
|
742.55 | 253.41B | 0 | 0 | 0 | 0.00 |
VB
Vanguard Small Cap Etf
|
296.88 | 160.59B | 0 | 0 | 0 | 0.00 |
QQQ
Invesco Qqq Trust Series 1
|
682.12 | 124.43B | 0 | 0 | 0 | 0.00 |
ARK Genomic Revolution ETF Stock (ARKG) Latest News
Caris Life Sciences Inc (CAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
A14Y8G ETF Profile: Dividends, Returns (LS:A14Y8G) - TradingView
10X Genomics Inc (TXG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Absci Corp (ABSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Schrodinger Inc (SDGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Intellia Therapeutics Inc (NTLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
908 Devices Inc. (MASS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beam Therapeutics Inc (BEAM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How is ARKG Performing in the Current Market Environment - Kavout | AI
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
0CQL ETF Profile: Dividends, Returns (LSE:0CQL) - TradingView
Tempus AI Inc (TEM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Twist Bioscience Corp (TWST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cathie Wood’s ARK sells Figma stock, buys Scribe Therapeutics By Investing.com - Investing.com Nigeria
BioNTech’s Pumitamig Hopes Face a Reality Check as ARK Exits and the Stock Hovers at a Technical C - Ad-hoc-news.de
1ARG ETF Profile: Dividends, Returns (LSE:1ARG) - TradingView
A408AY ETF Profile: Dividends, Returns (LS:A408AY) - TradingView
Cathie Wood Sells HOOD, Buys More SPCX: What ARK's Latest Moves SignalARK Innovation ETF (BATS:ARKK) - Benzinga
🧬 DNA Stock | Is Ginkgo Bioworks The Next Amazon Stock? Eswatini (usFV0zKJfR) - Mshale
Cathie Wood’s ARK Sells HOOD Stock Again – Even As Robinhood Hits 1M Gold Cards, Launches Platinum Card - Yahoo Finance
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
How (ARKG) Movements Inform Risk Allocation Models - Stock Traders Daily
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Cathie Wood's Ark Invest sold $7.4 million of BioNTech stock - MSN
Cathie Wood buys $2 million of tumbling AI stock - MSN
ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026. - Pluang
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins? - Yahoo Finance
These 15 Funds Cost Investors Billions Over the Past Decade - Morningstar
ARG1 ETF Profile: Dividends, Returns (FWB:ARG1) - TradingView
ETFs Investing in GeneDx Holdings Corp. Class A Stocks - TradingView
ARG1 ETF Profile: Dividends, Returns (MUN:ARG1) - TradingView
Cathie Wood’s ARK Invest adds another $57M to SpaceX, sells $39M stake in AMD - Seeking Alpha
Cathie Wood Just Bet Big on This Biotech Stock - webull.com
Cathie Wood Dumps $11.7 Million in AMD, Redirects Capital to SpaceX and CoreWeave - finance.biggo.com
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders - Stocktwits
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names - MSN
ARKG ETF Profile: Dividends, Returns (VANTAGE:ARKG) - TradingView
Cathie Wood is selling this high-flying stock. Is it a buy? - MSN
Cathie Wood Is Selling This High-Flying Stock. Is It a Buy? - The Motley Fool
ARKGCO ETF Profile: Dividends, Returns (BVC:ARKGCO) - TradingView
AAKG ETF Profile: Dividends, Returns (TRADEGATE:AAKG) - TradingView
AAKG ETF Profile: Dividends, Returns (DUS:AAKG) - TradingView
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock - AOL.com
Cathie Wood is loading up on this biotech stock. Is it a no-brainer buy? - MSN
ARG1 ETF Profile: Dividends, Returns (XETR:ARG1) - TradingView
Cathie Wood Sold $8 Million of AMD Stock in a Single Day - AOL.com
AAKG ETF Profile: Dividends, Returns (GETTEX:AAKG) - TradingView
What This $1.1 Million Insider Sale at Accelerant Means for Investors - AOL.com
AAKG ETF Profile: Dividends, Returns (XETR:AAKG) - TradingView
ARK Genomic Revolution ETF Stock (ARKG) Financials Data
There is no financial data for ARK Genomic Revolution ETF (ARKG). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.12%
0.30%
Cap:
|
Volume (24h):